Tezel Gizem, Timur Selin Seda, Bozkurt İsmail, Türkoğlu Ö Faruk, Eroğlu İpek, Nemutlu Emirhan, Öner Levent, Eroğlu Hakan
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University.
Department of Neurosurgery, Çankırı State Hospital.
Chem Pharm Bull (Tokyo). 2019 Oct 1;67(10):1030-1041. doi: 10.1248/cpb.c19-00511. Epub 2019 Jul 24.
Alzheimer's Disease (AD) is one of the most challenging diseases faced by humankind. AD is still not classified as curable because of the complex structure of pathologies underlying it. As the mean life expectancy of the world population constantly increases, the prevalence of AD and treatment costs for AD also grow rapidly. Current state of the art for AD treatment mainly consists of palliative therapy aimed at providing symptomatic relief and improving the standard of living in patients with AD. However, different research groups are working on more effective and safe drug delivery options aimed at both symptomatic relief and treatment of the underlying mechanisms. In this review, the current prevalence of AD, health costs, pathologies, and available treatment options including the ones in the market and/or under trial have been reviewed. Data in the existing literature have been presented, and future opportunities have been discussed. It is our belief that these nanotechnological products provide the required efficacy and safety profiles to enable these formulations go through phase studies and enter the market after regulatory authority approval, as with cancer. Last, but not the least the metabolomic studies will be providing useful informative data on the early diagnosis of AD, thus may be clinical implications might be delayed with the administration of therapeutic agents at the initial state of the disease.
阿尔茨海默病（AD）是人类面临的最具挑战性的疾病之一。由于其潜在病理结构复杂，AD仍未被归类为可治愈疾病。随着世界人口平均预期寿命不断提高，AD的患病率和治疗成本也迅速增长。目前AD治疗的技术水平主要包括姑息治疗，旨在缓解症状并提高AD患者的生活水平。然而，不同的研究团队正在致力于开发更有效、更安全的药物递送方案，以实现症状缓解和对潜在机制的治疗。在本综述中，我们对AD的当前患病率、医疗成本、病理以及可用的治疗方案（包括市场上和/或正在试验中的方案）进行了综述。我们呈现了现有文献中的数据，并讨论了未来的机遇。我们相信，这些纳米技术产品具备所需的疗效和安全性，能够使这些制剂像癌症治疗药物那样通过各阶段研究，并在获得监管机构批准后进入市场。最后但同样重要的是，代谢组学研究将为AD的早期诊断提供有用的信息数据，因此在疾病初始阶段给予治疗药物可能会延迟其临床意义。
